Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1992 1
1993 2
1995 4
1996 2
1997 2
1998 5
1999 15
2000 18
2001 18
2002 17
2003 21
2004 15
2005 17
2006 12
2007 12
2008 10
2009 7
2010 6
2011 14
2012 13
2013 12
2014 15
2015 12
2016 7
2017 9
2018 12
2019 11
2020 6
2021 9
2022 8
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

293 results

Results by year

Filters applied: . Clear all
Page 1
Ripasudil-Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials.
Tanihara H, Yamamoto T, Aihara M, Kawakita K, Kojima S, Kanazawa M, Nojima T, Suganami H; K-232 Clinical Study Group. Tanihara H, et al. Am J Ophthalmol. 2023 Apr;248:35-44. doi: 10.1016/j.ajo.2022.11.017. Epub 2022 Nov 21. Am J Ophthalmol. 2023. PMID: 36410471 Free article. Clinical Trial.
PURPOSE: To confirm the superiority of the intraocular pressure (IOP)-lowering effect of the ripasudil-brimonidine fixed-dose combination (RBFC, K-232) to ripasudil 0.4% or brimonidine 0.1% ophthalmic solution. ...METHODS: Patients with primary open-angle glaucoma o …
PURPOSE: To confirm the superiority of the intraocular pressure (IOP)-lowering effect of the ripasudil-brimonidine fixed-dose combina …
Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
Inatani M, Orii Y, Iwasaki K, Arimura S, Sunagawa H, Shiokawa M, Inoue K, Sakono T, Sakono T, Kuwamura R, Yoshida A, Oi J, Kuwayama Y, Kano K, Kido N, Matsuyama A, Ozaki M, Abe H, Inoue C, Nakagawa S, Musashi K, Kanamori A, Lee J, Otani S, Aoki R, Tanabe H, Nakakura S, Suzuki K, Sagara T, Saito Y, Sameshima M, Urahashi M, Watanabe-Kitamura F, Inoue T, Kagaya F, Murai Y, Mori S, Ueda K, Kurimoto T, Yamada-Nakanishi Y, Nakamura M, Yamashita T, Ishiyama S, Manabe S, Takaki K, Hayashi K, Ishida A, Tsutsui A, Manabe K, Tanito M. Inatani M, et al. Adv Ther. 2023 Sep;40(9):4074-4092. doi: 10.1007/s12325-023-02589-9. Epub 2023 Jul 15. Adv Ther. 2023. PMID: 37452961 Free PMC article. Clinical Trial.
INTRODUCTION: This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive t …
INTRODUCTION: This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and …
Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine.
Tanihara H, Yamamoto T, Aihara M, Koizumi N, Minami H, Kojima S, Isobe T, Kanazawa M, Suganami H; K-232 Clinical Study Group. Tanihara H, et al. Adv Ther. 2023 Aug;40(8):3559-3573. doi: 10.1007/s12325-023-02534-w. Epub 2023 Jun 18. Adv Ther. 2023. PMID: 37330927 Free PMC article. Clinical Trial.
Subjects received twice-daily instillation of RBFC ripasudil brimonidine (group A), ripasudil brimonidine RBFC (group B), or brimonidine RBFC ripasudil (group C). ...Transient morphologic changes in corneal endothelial cells occurred for up to several hours w …
Subjects received twice-daily instillation of RBFC ripasudil brimonidine (group A), ripasudil brimonidine RBFC (group B), or …
Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study.
Tanihara H, Yamamoto T, Aihara M, Koizumi N, Fukushima A, Kawakita K, Kojima S, Nakamura T, Suganami H; K-232 Clinical Study Group. Tanihara H, et al. Graefes Arch Clin Exp Ophthalmol. 2024 Aug;262(8):2579-2591. doi: 10.1007/s00417-024-06388-y. Epub 2024 Mar 2. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 38430227 Free PMC article. Clinical Trial.
PURPOSE: To evaluate the long-term efficacy and safety of ripasudil-brimonidine fixed-dose combination (RBFC), a new intraocular pressure (IOP)-lowering medication for glaucoma and ocular hypertension (OHT). ...
PURPOSE: To evaluate the long-term efficacy and safety of ripasudil-brimonidine fixed-dose combination (RBFC), a new intraocular pres …
Effect of brimonidine tartrate 0.15% on scotopic pupil size and upper eyelid position: controlled trial.
Tuncer I, Bilgin S, Zengin MÖ, Mangan MS, Karaca A, Doğan C, Çınar E. Tuncer I, et al. Eye (Lond). 2021 Feb;35(2):672-675. doi: 10.1038/s41433-020-1007-9. Epub 2020 Jun 9. Eye (Lond). 2021. PMID: 32518394 Free PMC article. Clinical Trial.
BACKGROUND: To evaluate the effect of brimonidine tartrate 0.15% ophthalmic solution on pupil size under scotopic condition and upper eyelid position. METHODS: This study comprised 72 eyes of 36 healthy subjects. A single drop of brimonidine tartrate 0 …
BACKGROUND: To evaluate the effect of brimonidine tartrate 0.15% ophthalmic solution on pupil size under scotopic condition an …
Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.
McLaurin E, Cavet ME, Gomes PJ, Ciolino JB. McLaurin E, et al. Optom Vis Sci. 2018 Mar;95(3):264-271. doi: 10.1097/OPX.0000000000001182. Optom Vis Sci. 2018. PMID: 29461408 Free PMC article. Clinical Trial.
PURPOSE: The aim of this study was to evaluate the safety and efficacy of brimonidine tartrate ophthalmic solution 0.025% for the treatment of ocular redness. METHODS: In this single-center, double-masked, phase 3 clinical trial, adult subjects with baseline redness …
PURPOSE: The aim of this study was to evaluate the safety and efficacy of brimonidine tartrate ophthalmic solution 0.025% for …
Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
Katz G, Dubiner H, Samples J, Vold S, Sall K. Katz G, et al. JAMA Ophthalmol. 2013 Jun;131(6):724-30. doi: 10.1001/jamaophthalmol.2013.188. JAMA Ophthalmol. 2013. PMID: 23579344 Clinical Trial.
INTERVENTION: Topical administration of study medication (fixed-combination brinzolamide, 1%, and brimonidine, 0.2%; brinzolamide, 1%; or brimonidine, 0.2%) 1 drop 3 times daily for 3 months. ...A total of 129 patients experienced at least 1 treatment-related advers …
INTERVENTION: Topical administration of study medication (fixed-combination brinzolamide, 1%, and brimonidine, 0.2%; brinzolamide, 1% …
Improved Presbyopic Vision With Miotics.
Abdelkader A. Abdelkader A. Eye Contact Lens. 2015 Sep;41(5):323-7. doi: 10.1097/ICL.0000000000000137. Eye Contact Lens. 2015. PMID: 25806674 Clinical Trial.
The treatment group (n=30 eyes) received single dose of 2.25% carbachol plus 0.2% brimonidine eye drops. The control group (n=18 eyes) received placebo drops. Drops were given to all subjects in a masked fashion, in their nondominant eye. ...RESULTS: Statistically signific …
The treatment group (n=30 eyes) received single dose of 2.25% carbachol plus 0.2% brimonidine eye drops. The control group (n=18 eyes …
Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial.
Kim KE, Lee CK, Shin J, Kim Y, Rho S. Kim KE, et al. Sci Rep. 2023 Apr 7;13(1):5700. doi: 10.1038/s41598-023-31726-1. Sci Rep. 2023. PMID: 37029145 Free PMC article. Clinical Trial.
This multicenter (four institutions), randomized, investigator-masked, parallel-group clinical trial evaluated and compared the efficacy and safety of preservative-free and preserved brimonidine tartrate 0.15% in open-angle glaucoma and ocular hypertension. Sixty ey …
This multicenter (four institutions), randomized, investigator-masked, parallel-group clinical trial evaluated and compared the efficacy and …
293 results